+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer

A robust six-gene prognostic signature for prediction of both disease-free and overall survival in non-small cell lung cancer

Journal of Translational Medicine 17(1): 152

The high mortality of patients with non-small cell lung cancer (NSCLC) emphasizes the necessity of identifying a robust and reliable prognostic signature for NSCLC patients. This study aimed to identify and validate a prognostic signature for the prediction of both disease-free survival (DFS) and overall survival (OS) of NSCLC patients by integrating multiple datasets. We firstly downloaded three independent datasets under the accessing number of GSE31210, GSE37745 and GSE50081, and then performed an univariate regression analysis to identify the candidate prognostic genes from each dataset, and identified the gene signature by overlapping the candidates. Then, we built a prognostic model to predict DFS and OS using a risk score method. Kaplan-Meier curve with log-rank test was used to determine the prognostic significance. Univariate and multivariate Cox proportional hazard regression models were implemented to evaluate the influences of various variables on DFS and OS. The robustness of the prognostic gene signature was evaluated by re-sampling tests based on the combined GEO dataset (GSE31210, GSE37745 and GSE50081). Furthermore, a The Cancer Genome Atlas (TCGA)-NSCLC cohort was utilized to validate the prediction power of the gene signature. Finally, the correlation of the risk score of the gene signature and the Gene set variation analysis (GSVA) score of cancer hallmark gene sets was investigated. We identified and validated a six-gene prognostic signature in this study. This prognostic signature stratified NSCLC patients into the low-risk and high-risk groups. Multivariate regression and stratification analyses demonstrated that the six-gene signature was an independent predictive factor for both DFS and OS when adjusting for other clinical factors. Re-sampling analysis implicated that this six-gene signature for predicting prognosis of NSCLC patients is robust. Moreover, the risk score of the gene signature is correlated with the GSVA score of 7 cancer hallmark gene sets. This study provided a robust and reliable gene signature that had significant implications in the prediction of both DFS and OS of NSCLC patients, and may provide more effective treatment strategies and personalized therapies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 066783714

Download citation: RISBibTeXText

PMID: 31088477

DOI: 10.1186/s12967-019-1899-y

Related references

Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery. European Journal of Nuclear Medicine and Molecular Imaging 45(2): 207-217, 2018

Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non-Small Cell Lung Cancer. Radiology 281(3): 947-957, 2016

A four-gene signature from NCI-60 cell line for survival prediction in non-small cell lung cancer. Clinical Cancer Research 15(23): 7309-7315, 2009

Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer. Asian Cardiovascular and Thoracic Annals 14(2): 139-144, 2006

A three microRNA-based prognostic signature for small cell lung cancer overall survival. Journal of Cellular Biochemistry 2018:, 2018

Loss of 4q21.23-22.1 is a prognostic marker for disease free and overall survival in non-small cell lung cancer. Plos one 9(12): E113315, 2014

RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. Journal of Clinical Oncology 22(10): 1878-1885, 2004

Prediction of postoperative recurrence-free survival in non-small cell lung cancer by using an internationally validated gene expression model. Clinical Cancer Research 17(9): 2934-2946, 2011

Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Medical Oncology 30(1): 352, 2013

An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer. Oncotarget 7(52): 86561-86572, 2016

Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clinical Cancer Research 14(22): 7397-7404, 2008

Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America 108(17): 7160-7165, 2011

Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer. Anticancer Research 32(11): 5087-5091, 2012

Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab. Journal of Clinical Pharmacology 54(3): 253-257, 2014

Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival. Journal of Thoracic and Cardiovascular Surgery 134(3): 638-643, 2007